MedTrace Logo

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

NCT00352612 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.

Conditions

  • Staphylococcal Infection
  • Abscess
  • Staphylococcal Skin Infection
  • Folliculitis

Interventions

DRUG

clindamycin

clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days

DRUG

cephalexin

cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days

Sponsors & Collaborators

Principal Investigators

  • Aaron E Chen, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-05-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352612 on ClinicalTrials.gov